It has been calculated that 30% to 40% of dialysis patients fail to produce antibodies to Hepatitis B antigen after vaccination towards Hepatitis B virus.
Several authors have reported on the benefit of thymopentin as adjuvant to vaccine against Hepatitis B virus in patients receiving regular dialysis.
However, consistent information on this issue is still lacking.
Dr Fabrizi and colleagues from Italy evaluated efficacy and safety of thymopentin as adjuvant to Hepatitis B vaccine in dialysis patients.
The research team performed a systematic review with a meta-analysis of clinical trials.
|The pooled odds ratio of failure to respond to Hepatitis B virus vaccine was 0.68|
|Alimentary Pharmacology & Therapeutics|
The team used the random effects model of DerSimonian and Laird, along with heterogeneity and sensitivity analyses.
The researchers identified 11 studies involving 272 unique patients with end-stage renal disease.
Only prospective, controlled trials were included.
The team observed no increase in seroresponse rate among patients receiving thymopentin plus Hepatitis B virus vaccine vs controls receiving Hepatitis B virus vaccine alone.
The team found that the pooled odds ratio of failure to respond to Hepatitis B virus vaccine was 0.68.
No heterogeneity was found.
However, the team noted that thymopentin significantly improved the seroresponse rate in the subgroup of trials based on greater thymopentin doses.
Dr Fabrizi's team commented, “Our meta-analysis showed that thymopentin significantly improved the seroresponse rate towards Hepatitis B vaccine only in dialysis patients treated with higher thymopentin doses.”
“The limited number of patients precluded definitive conclusions.”